CN114712427B - Application of peach root medicine - Google Patents
Application of peach root medicine Download PDFInfo
- Publication number
- CN114712427B CN114712427B CN202210080060.3A CN202210080060A CN114712427B CN 114712427 B CN114712427 B CN 114712427B CN 202210080060 A CN202210080060 A CN 202210080060A CN 114712427 B CN114712427 B CN 114712427B
- Authority
- CN
- China
- Prior art keywords
- peach
- root
- fibrosis
- kidney
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000006040 Prunus persica var persica Nutrition 0.000 title claims abstract description 68
- 239000003814 drug Substances 0.000 title claims abstract description 42
- 240000006413 Prunus persica var. persica Species 0.000 title 1
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 66
- 206010016654 Fibrosis Diseases 0.000 claims abstract description 24
- 230000004761 fibrosis Effects 0.000 claims abstract description 23
- 206010023421 Kidney fibrosis Diseases 0.000 claims abstract description 12
- 210000000056 organ Anatomy 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 5
- 241000169680 Aphloia theiformis Species 0.000 claims description 23
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 17
- 238000002156 mixing Methods 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 12
- 239000002775 capsule Substances 0.000 claims description 11
- 238000004140 cleaning Methods 0.000 claims description 11
- 238000000227 grinding Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000010298 pulverizing process Methods 0.000 claims description 11
- 239000003826 tablet Substances 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000006188 syrup Substances 0.000 claims description 6
- 235000020357 syrup Nutrition 0.000 claims description 6
- 238000007493 shaping process Methods 0.000 claims description 5
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 238000000643 oven drying Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000003902 lesion Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 9
- 108090000623 proteins and genes Proteins 0.000 abstract description 6
- 210000000651 myofibroblast Anatomy 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 201000002793 renal fibrosis Diseases 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000000126 substance Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000003734 kidney Anatomy 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 15
- 210000004185 liver Anatomy 0.000 description 15
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- 229920002472 Starch Polymers 0.000 description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 9
- 229960002591 hydroxyproline Drugs 0.000 description 9
- 235000019698 starch Nutrition 0.000 description 9
- 239000008107 starch Substances 0.000 description 9
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 9
- 208000004608 Ureteral Obstruction Diseases 0.000 description 8
- 102000008186 Collagen Human genes 0.000 description 7
- 108010035532 Collagen Proteins 0.000 description 7
- 229920001436 collagen Polymers 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000001575 pathological effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 208000034189 Sclerosis Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 3
- 238000001647 drug administration Methods 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000003176 fibrotic effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 206010020718 hyperplasia Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 235000003840 Amygdalus nana Nutrition 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 206010019670 Hepatic function abnormal Diseases 0.000 description 1
- 206010019695 Hepatic neoplasm Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028594 Myocardial fibrosis Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000220299 Prunus Species 0.000 description 1
- 235000011432 Prunus Nutrition 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 206010046406 Ureteric obstruction Diseases 0.000 description 1
- PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
- 150000004056 anthraquinones Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 230000002206 pro-fibrotic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000014774 prunus Nutrition 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to the technical field of traditional Chinese medicines, and in order to discover and verify the medicinal value of peach roots and extracts thereof in the aspect of disease treatment, the invention provides application of a peach root medicament, and application of a peach root treatment substance in preparing medicaments for improving or/and treating organ fibrosis or/and hardening diseases; in particular for the treatment of renal fibrosis; the result shows that the peach root has good effect of resisting kidney fibrosis lesions, can reduce the number of UFO kidney fibrosis promoting myofibroblasts, and remarkably inhibit the RNA and protein levels of fibrosis genes.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to application of a peach root medicine.
Background
Fibrosis is essentially an excessive wound healing response that can lead to progressive structural remodeling of almost all tissues and organs, leading to organ failure and patient death. In the industrialized world, up to 45% of deaths are caused by organ fibrosis. There is a clinical lack of targeted therapeutic drugs for organ fibrosis.
Peach tree root, root or root bark of peach trunk Persica (l.) Batsch or mountain peach trunk davidiana (carr.) frank of Prunus genus of Rosaceae family. Bitter and flat, and nontoxic. Efficacy: clear heat and promote diuresis, activate blood and relieve pain, stop malaria and kill parasites. Modern researches have shown that peach root has good effects of anti-inflammatory, anti-tumor, antibacterial, immunity enhancing, and hemostatic, and its main ingredients contain substances such as ketones, anthraquinone, phenol and tannins, saccharides, triterpenes, and phytosterol; studies have also shown that the ethanol extract of peach root inhibits tumor growth in vivo and inhibits the growth of liver cancer HepG2 cells in vitro by inducing cell cycle arrest and migration.
However, no related report on the application value of peach root and extract thereof in the traditional Chinese medicine for treating fibrosis diseases is found at present, and the document takes the most common kidney and liver fibrosis diseases as an example, and demonstrates the medicinal value of peach root and extract thereof in various organ fibrosis lesions.
Disclosure of Invention
The invention aims to provide an application of a drug containing peach roots in preparing a drug for improving or/and treating organ fibrosis or/and sclerosis diseases, in particular to an application in treating kidney fibrosis diseases; the result shows that the peach root has good effect of resisting kidney fibrosis lesions, can reduce the number of UFO kidney fibrosis promoting myofibroblasts, and remarkably inhibit the RNA and protein levels of fibrosis genes.
The embodiment of the invention is realized by the following technical scheme:
the application of peach root medicine in preparing medicine for improving and/or treating organ fibrosis and/or sclerosis.
Further, the peach tree root is selected from mountain peach tree root and/or peach tree root extract thereof.
Further, the organ fibrosis disease includes: kidney fibrosis, spleen fibrosis, pancreas fibrosis, lung fibrosis, liver fibrosis.
Further, the organ-hardening disease includes: nephrosclerosis, splenosclerosis, pancreatic sclerosis, pulmonary sclerosis and liver cirrhosis.
Further, the peach root treatment comprises peach root and/or peach root extract and pharmaceutically acceptable auxiliary materials.
Further, the ratio of the weight of the peach tree root to the total weight of the medicine is 60-80:100.
Further, the ratio of the weight of the peach tree root to the total weight of the medicament is 70:100.
Further, the dosage form of the medicament comprises tablets, capsules, pills, powder, granules or syrup.
Further, the preparation method of the drug containing peach tree roots comprises the following steps: cleaning root of fructus Persicae, cutting, oven drying at 50-80deg.C, pulverizing, and grinding; adding pharmaceutically acceptable auxiliary materials according to a proportion, adding water, mixing, shaping and drying; then the medicine is prepared into the required dosage form.
The technical scheme of the embodiment of the invention has at least the following advantages and beneficial effects:
1. the invention discovers new medicinal value for peach tree roots, peach tree root extracts and combinations thereof, and is used for preparing medicaments for improving or/and treating organ fibrosis or/and hardening, thereby developing a new field for the application of peach tree roots and peach tree root extracts.
2. The peach root medicament has remarkable treatment effect on kidney fibrosis and liver fibrosis lesions, is safe and nontoxic, and is expected to be used for preparing medicaments for treating multiple organ fibrosis, especially kidney fibrosis and liver fibrosis lesions, more preferably, kidney fibrosis caused by renal tubular expansion, interstitial hyperplasia and collagen deposition caused by ureter obstruction and chronic CCl 4 The induced liver fibrosis and liver cirrhosis lesion medicine has obvious application prospect and clinical application value.
Drawings
In order to more clearly illustrate the technical solution of the embodiments of the present invention, the drawings that are required to be used in the embodiments will be briefly described.
FIG. 1 shows the pathological staining results of normal kidneys, model kidneys and dosing kidneys provided by the present invention;
FIG. 2 shows the hydroxyproline quantification results of normal kidneys, model kidneys and dosing kidneys provided by the present invention;
FIG. 3 shows the pathological staining results of normal liver, model liver and administration liver provided by the present invention;
FIG. 4 shows the hydroxyproline quantification results for normal liver, model liver and dosing liver provided by the present invention;
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention more clear, the technical solutions of the embodiments of the present invention will be clearly and completely described below. The specific conditions are not noted in the examples and are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Example 1 peach root tablet
Cleaning mountain peach root, cutting, drying at 65deg.C, pulverizing, grinding, mixing 30g mountain peach root powder with 70g starch, adding water, shaping, drying, granulating, adding talcum powder and magnesium stearate, mixing, and tabletting to obtain 100 tablets.
EXAMPLE 2 peach root Capsule
Cleaning mountain peach tree root, cutting, drying at 65deg.C, pulverizing, grinding, mixing 30g mountain peach tree root powder with 70g starch, and making into capsule (100 capsules).
EXAMPLE 3 peach root granule
Cleaning mountain peach tree root, cutting, drying at 65deg.C, pulverizing, grinding, mixing 30g mountain peach tree root powder with 70g starch and vitamin C, bagging, and making into about 100 bags.
Example 4 peach root tablet
Cleaning mountain peach root, cutting, drying at 50deg.C, pulverizing, grinding, mixing 40g mountain peach root powder with 60g starch, adding water, shaping, drying, granulating, adding talcum powder and magnesium stearate, mixing, and tabletting to obtain 100 tablets.
EXAMPLE 5 peach root Capsule
Cleaning mountain peach tree root, cutting, drying at 50deg.C, pulverizing, grinding, mixing 40g mountain peach tree root powder with 60g starch, and making into capsule (100 capsules).
EXAMPLE 6 peach root granule
Cleaning mountain peach tree root, cutting, drying at 50deg.C, pulverizing, grinding, mixing 40g mountain peach tree root powder with 60g starch and vitamin C, bagging, and making into about 100 bags.
EXAMPLE 7 peach root tablet
Cleaning mountain peach root, cutting, drying at 80deg.C, pulverizing, grinding, mixing 20g mountain peach root powder with 80g starch, adding water, shaping, drying, granulating, adding talcum powder and magnesium stearate, mixing, and tabletting to obtain 100 tablets.
Example 8 peach root Capsule
Cleaning mountain peach tree root, cutting, oven drying at 80deg.C, pulverizing, grinding, mixing 20g mountain peach tree root powder with 80g starch, and making into capsule (100 capsules).
Example 9 peach root granule
Cleaning mountain peach tree root, cutting, drying at 80deg.C, pulverizing, grinding, mixing 20g mountain peach tree root powder with 80g starch and vitamin C, bagging, and making into about 100 bags.
EXAMPLE 10 peach root syrup
Dissolving 30g of mountain peach root with ethanol, adding glucose syrup, and finally adding deionized water to 100 ml.
EXAMPLE 11 peach root syrup
Dissolving 40g of mountain peach root with ethanol, adding glucose syrup, and finally adding deionized water to 100 ml.
Experimental example 1 Effect of peach root drug on renal fibrosis lesions
Unilateral Ureteral Obstruction (UUO) model
1.1 subjects: 20 male C57BL/6J mice, 8 weeks old, were randomly selected, anesthetized with 1% pentobarbital, left ureteral ligation was performed, and then randomly divided into model groups and dosing groups, each group having 10 animals.
1.2 methods of administration and observation:
model group: the administration is SPF-class mice maintenance feed.
Drug administration group: the medicine is medicine-containing feed; namely, tablet+SPF-grade mice of example 1 of the present invention maintained the feed.
After operation: the model group was given SPF grade size mice maintenance feed; administration group administration of medicated feed, i.e., tablet+spf grade mice maintenance feed of example 1 of the present invention; feeding for 7 days respectively. On day 8, taking the right kidney (non-ligatured kidney) of the model group as a normal control, the left kidney (UUO kidney) of the model group as a fibrotic lesion kidney model, and the left kidney (UUO kidney+drug) of the administration group as a drug administration fibrotic kidney after drug intervention;
1.3 experimental results:
the normal kidney, model kidney and administration kidney were examined and analyzed, respectively, and the results are shown in FIGS. 1-2.
From the results of FIGS. 1-2, it can be seen that: the pathological results of the normal kidney, the model kidney and the administration kidney are compared with the pathological staining (HE and Masson) results, and the pathological results of the administration kidney are obviously superior to those of the other two groups, so that the peach tree root can obviously inhibit tubular expansion, interstitial hyperplasia and collagen deposition caused by unilateral ureteral ligation (UUO); the hydroxyproline quantification finds that the treatment of peach roots can obviously reduce the content of the hydroxyproline from the UUO kidney collagen. Immunohistochemical staining of a-SMA showed that peach roots reduced the number of UUO kidney pro-fibrotic myofibroblasts cells. Meanwhile, RT-PCR and western blot results show that peach roots remarkably inhibit the RNA and protein levels of fibrosis genes Fibronectin (Fn, col1a1, a-SMA).
Experimental example 2 Effect of peach root drug on liver fibrosis lesions
Model of carbon tetrachloride (CCl 4) -induced liver fibrosis
2.1 subjects: 30 male ICR mice of 6-8 weeks of age were randomly selected and randomly divided into three groups: normal group, model group, dosing group; each group of 10.
2.2 methods of administration and observation:
normal group: mice were given twice weekly intraperitoneal injections of olive oil (2 ul/g body weight) +feed;
model group: mice were given twice weekly intraperitoneal injections of 20% cci 4 (in olive oil, 2ul/g body weight) +feed;
drug administration group: mice were given intraperitoneal injections of 20% cci 4 (in olive oil, 2ul/g body weight) +medicated feed; the feed containing the medicine comprises the following components: granule+SPF-grade mice of example 3 of the present invention maintained feed.
Taking the liver for fibrosis index analysis, wherein the analysis comprises quantitative PCR analysis of fibrosis related gene expression; paraffin sections of liver tissue were stained with Hematoxylin Eosin (HE) and sirius red; analyzing the hydroxyproline content of the fiber collagen source in the liver tissue by using a hydroxyproline content measurement test box; liver function (ALT) was measured using serum.
2.3 experimental results:
the results of the detection and analysis of the liver of the normal group, the liver of the model group and the liver of the administration group are shown in fig. 3-4.
From the results of fig. 3-4, it can be seen that: model group mice passed chronic CCl 4 Injection induces significant liver fibrosis/cirrhosis lesions. CCl relative to normal group of mouse livers 4 Atrophy occurs in the liver of the treated mice, and the liver surface loses smooth touch and takes a rough particle shape; the administration group mice can obviously improve CCl due to the administration of the peach tree root drug-containing feed 4 The atrophy caused by the method can restore the color of the liver. The result of pathological staining (HE and sirius scarlet) shows that peach root can improve CCl 4 Liver nodule cirrhosis and fibrosis caused by this, hydroxyproline quantification reveals that peach roots significantly reduce CCl 4 The collagen hydroxyproline content of the liver of the treated mice is corresponding to the collagen hydroxyproline content, and quantitative RT-PCR indicates that the expression level of the liver fibrosis genes a-SMA and Fn of the treated mice with peach root medicines is obviously lower than that of a model group. Notably, peach roots can reduce CCl 4 Treatment of mice serum AST (glutamate oxaloacetic transaminase) levels improves impaired liver function. From the results, peach root medicine has the effect of improving CCl 4 Liver fibrosis.
In conclusion, the peach root drug has remarkable treatment effect on kidney fibrosis and liver fibrosis lesions, especially on ureters with a single sideRenal tubular dilation caused by ligation (UUO), drug for renal fibrosis caused by interstitial proliferation and collagen deposition, and chronic CCl 4 The induced hepatic fibrosis lesion has a remarkable treatment effect; therefore, the peach tree root and the pharmaceutical active ingredient derived from the peach tree root are expected to be used for improving multi-organ fibrosis, such as: pulmonary fibrosis, myocardial fibrosis and pancreatic fibrosis.
Claims (5)
1. An application of peach root medicine, which is characterized in that peach root or/and peach root extract is used as the only active ingredient in the preparation of medicine for improving or/and treating organ fibrosis or/and hardening diseases, wherein the organ fibrosis or/and hardening diseases are as follows: kidney fibrosis, liver fibrosis or cirrhosis;
the preparation method of the peach root drug comprises the following steps: cleaning root of peach tree, cutting, oven drying at 50-80deg.C, pulverizing, and grinding; adding pharmaceutically acceptable auxiliary materials according to a proportion, adding water, mixing, shaping and drying; then the medicine is prepared into the required dosage form.
2. The use of peach tree root medicament according to claim 1, wherein the peach tree root is selected from the group consisting of mountain peach tree root and/or peach tree root extract.
3. The use of peach root medicament according to claim 1, wherein the ratio of the weight of the peach root to the total weight of the medicament is 20-40:100.
4. The use of peach root medicament according to claim 3, wherein the ratio of the weight of the peach root to the total weight of the medicament is 30:100.
5. The use of peach root medicament according to claim 1, wherein the medicament is in the form of a tablet, capsule, pill, powder, granule or syrup.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210080060.3A CN114712427B (en) | 2022-01-24 | 2022-01-24 | Application of peach root medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210080060.3A CN114712427B (en) | 2022-01-24 | 2022-01-24 | Application of peach root medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114712427A CN114712427A (en) | 2022-07-08 |
| CN114712427B true CN114712427B (en) | 2024-04-12 |
Family
ID=82236233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210080060.3A Active CN114712427B (en) | 2022-01-24 | 2022-01-24 | Application of peach root medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114712427B (en) |
-
2022
- 2022-01-24 CN CN202210080060.3A patent/CN114712427B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| 管鹏声.肾病综合征治疗经验.云南中医学院学报.1996,(04),第34-37页. * |
| 郎晓猛等.刘建平治疗脾胃病用药心得.河北科学技术出版社,2019,(第1版),第207页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114712427A (en) | 2022-07-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105769891B (en) | Low polarity rare ginsenoside mixture and application thereof | |
| AU2014305430B2 (en) | Application of andrographolide in the preparation of a pharmaceutical for treatment of inflammatory bowel disease, andrographolide enteric targeting micropellet, and method for preparation thereof | |
| CN110520146A (en) | A kind of new application of the source of people fibroblast growth factor of long-actingization mutation | |
| KR101145248B1 (en) | Herbal medicine composition for the inhibition of angiogenesis | |
| CN111759853B (en) | Pharmaceutical composition and application thereof | |
| WO2023065860A1 (en) | Method for extracting phenolic glycosides from lamiophlomis rotata and use of phenolic glycosides in preparation of drugs for preventing and treating hepatic fibrosis or in health care products | |
| EP2609922B1 (en) | Pharmaceutical composition for treating chronic liver disease and use thereof | |
| EP1549329B1 (en) | Extract with anti-tumor and anti-poisonous activity | |
| WO2002076474A1 (en) | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
| CN115337356A (en) | Pharmaceutical composition for treating rheumatoid arthritis and preparation method thereof | |
| CN114712427B (en) | Application of peach root medicine | |
| CN110368445B (en) | Traditional Chinese medicine composition for treating psoriasis as well as preparation method and application thereof | |
| WO2022206250A1 (en) | Use of alkaloid compound in preparation of product for preventing and/or treating cardiac injury | |
| CN114869928B (en) | Traditional Chinese medicine composition for treating cerebrovascular diseases and application thereof | |
| CN107913273B (en) | The application of mesaconine | |
| CN106822152B (en) | Pharmaceutical composition and application thereof | |
| CN114028449B (en) | Traditional Chinese medicine compound medicine for treating fatty liver disease | |
| CN112826820B (en) | NLRP3 inhibitor and application thereof | |
| CN117100733B (en) | Salvianolic acid B and/or Notoginseng radix total saponin composition and its application | |
| CN113967229B (en) | Traditional Chinese medicine composition for treating phlebitis and preparation method and application thereof | |
| CN110251579B (en) | Anti-atherosclerosis pharmaceutical composition and preparation method thereof | |
| CN110179804B (en) | Application of Reversan in preparation of medicine for preventing and treating heart disease | |
| CN112535682B (en) | Application of Shaerweike ketone derivative in preparation of medicine | |
| CN106924272B (en) | Application of methyl salicylate glucoside in preparation of medicines for preventing and/or treating systemic lupus erythematosus and complications thereof | |
| CN114948930A (en) | Application of curcumenol in preparation of medicine for treating pulmonary hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |